Development of Shingles on Tofacitinib Despite Completion of Recombinant Varicella-Zoster Virus Vaccine Series

Braden Thomas; Joshua Moskow; Manuel Garza; Benjamin Warren; Bincy Abraham; Kerri Glassner

doi:10.14309/crj.0000000000001221

Development of Shingles on Tofacitinib Despite Completion of Recombinant Varicella-Zoster Virus Vaccine Series

Braden Thomas, Joshua Moskow, Manuel Garza, Benjamin Warren, Bincy Abraham, Kerri Glassner

Research output: Contribution to journal › Article › peer-review

Abstract

Shingles, also known as herpes zoster, is caused by the reactivation of the varicella-zoster virus (VZV). The risk of developing shingles increases with age, as well as in patients with weakened immune systems. Tofacitinib is a reversible Janus kinase inhibitor that suppresses the immune system and is used to treat autoimmune diseases, such as ulcerative colitis. Recombinant VZV vaccine is recommended for individuals taking tofacitinib and is highly effective at reducing the risk of shingles. This case report describes a patient with severe, refractory ulcerative colitis who developed shingles while on tofacitinib, despite prior vaccination with the recombinant VZV vaccine.

Original language	English (US)
Pages (from-to)	e01221
Journal	ACG case reports journal
Volume	10
Issue number	12
DOIs	https://doi.org/10.14309/crj.0000000000001221
State	Published - Dec 2023

Access to Document

10.14309/crj.0000000000001221

Cite this

@article{08da9bbe36664ec68e44acc2e2aa289b,

title = "Development of Shingles on Tofacitinib Despite Completion of Recombinant Varicella-Zoster Virus Vaccine Series",

abstract = "Shingles, also known as herpes zoster, is caused by the reactivation of the varicella-zoster virus (VZV). The risk of developing shingles increases with age, as well as in patients with weakened immune systems. Tofacitinib is a reversible Janus kinase inhibitor that suppresses the immune system and is used to treat autoimmune diseases, such as ulcerative colitis. Recombinant VZV vaccine is recommended for individuals taking tofacitinib and is highly effective at reducing the risk of shingles. This case report describes a patient with severe, refractory ulcerative colitis who developed shingles while on tofacitinib, despite prior vaccination with the recombinant VZV vaccine.",

author = "Braden Thomas and Joshua Moskow and Manuel Garza and Benjamin Warren and Bincy Abraham and Kerri Glassner",

note = "{\textcopyright} 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.",

year = "2023",

month = dec,

doi = "10.14309/crj.0000000000001221",

language = "English (US)",

volume = "10",

pages = "e01221",

journal = "ACG case reports journal",

issn = "2326-3253",

publisher = "American College of Gastroenterology",

number = "12",

}

TY - JOUR

T1 - Development of Shingles on Tofacitinib Despite Completion of Recombinant Varicella-Zoster Virus Vaccine Series

AU - Thomas, Braden

AU - Moskow, Joshua

AU - Garza, Manuel

AU - Warren, Benjamin

AU - Abraham, Bincy

AU - Glassner, Kerri

PY - 2023/12

Y1 - 2023/12

N2 - Shingles, also known as herpes zoster, is caused by the reactivation of the varicella-zoster virus (VZV). The risk of developing shingles increases with age, as well as in patients with weakened immune systems. Tofacitinib is a reversible Janus kinase inhibitor that suppresses the immune system and is used to treat autoimmune diseases, such as ulcerative colitis. Recombinant VZV vaccine is recommended for individuals taking tofacitinib and is highly effective at reducing the risk of shingles. This case report describes a patient with severe, refractory ulcerative colitis who developed shingles while on tofacitinib, despite prior vaccination with the recombinant VZV vaccine.

AB - Shingles, also known as herpes zoster, is caused by the reactivation of the varicella-zoster virus (VZV). The risk of developing shingles increases with age, as well as in patients with weakened immune systems. Tofacitinib is a reversible Janus kinase inhibitor that suppresses the immune system and is used to treat autoimmune diseases, such as ulcerative colitis. Recombinant VZV vaccine is recommended for individuals taking tofacitinib and is highly effective at reducing the risk of shingles. This case report describes a patient with severe, refractory ulcerative colitis who developed shingles while on tofacitinib, despite prior vaccination with the recombinant VZV vaccine.

U2 - 10.14309/crj.0000000000001221

DO - 10.14309/crj.0000000000001221

M3 - Article

C2 - 38107605

SN - 2326-3253

VL - 10

SP - e01221

JO - ACG case reports journal

JF - ACG case reports journal

IS - 12

ER -

Development of Shingles on Tofacitinib Despite Completion of Recombinant Varicella-Zoster Virus Vaccine Series

Abstract

Access to Document

Fingerprint

Cite this